Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT05639114
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ianalumab — DRUGianalumab s.c. monthly or quarterly
- Placebo — DRUGplacebo s.c. monthly
Study Details
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Key Dates
- Start date
- Mar 2, 2023
- Status verified
- Jun 2026
- Primary completion
- Mar 24, 2027
- Completion
- Mar 21, 2029
Study Design
- Enrollment
- 436 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ianalumab s.c. monthlyIanalumab s.c. monthly
- Experimental: Ianalumab s.c. quarterlyIanalumab s.c. quarterly
- Placebo Comparator: Placebo s.c. monthlyplacebo s.c. monthly
Primary Outcome Measure
Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ]
Locations (22)
Find similar trials in Anniston, AL
By condition
By specialty
Related Studies
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)Recruiting · Hospital for Special Surgery, New York · Chicago, Illinois
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Rheumatology Patient Registry and BiorepositoryRecruiting · Yale University · New Haven, Connecticut
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas